The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Initia-research; MAJ3 Capital
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Lilly; MSD; Pfizer
Research Funding - Agendia (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1. LICENSED
Travel, Accommodations, Expenses - AstraZeneca; MSD; Pfizer; Roche; Stemline Therapeutics
Other Relationship - MedSIR
Ipatasertib (IPA) combined with non-taxane chemotherapy (CT) for patients (pts) with previously treated advanced triple-negative breast cancer (aTNBC): The PATHFINDER phase IIa trial.
 
Elena Lopez-Miranda
Employment - MedSIR
Honoraria - AstraZeneca; Daiichi Sankyo; Lilly; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Seagen
Speakers' Bureau - AstraZeneca; Lilly
Travel, Accommodations, Expenses - Gilead Sciences; Roche
 
José Manuel Pérez García
Employment - MedSIR
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Roche; Seattle Genetics/Astellas
 
Maria Gion
Consulting or Advisory Role - AstraZeneca; Gilead Sciences
Speakers' Bureau - AstraZeneca; Gilead Sciences; Novartis; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Nuria Ribelles
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Novartis; Pfizer
Research Funding - Pfizer (Inst)
 
Patricia Cortez
No Relationships to Disclose
 
Jose Luis Alonso Romero
Consulting or Advisory Role - Daiichi Sankyo
Expert Testimony - Novartis; Pfizer
 
María Martínez-García
Honoraria - AstraZeneca; Lilly
Speakers' Bureau - Novocure
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Pfizer
 
Santiago Gonzalez- Santiago
Consulting or Advisory Role - AstraZeneca; Lilly; Seagen
Speakers' Bureau - GlaxoSmithKline; Novartis; Roche
Travel, Accommodations, Expenses - Clovis Oncology; Pfizer
 
Begoña Bermejo
Consulting or Advisory Role - AstraZeneca; MSD; Novartis; Pierre Fabre; Roche; Seagen
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Eisai; MSD; Palex; Pfizer; Roche; Seagen
 
Serafin Morales Murillo
No Relationships to Disclose
 
Vicente Carañana
No Relationships to Disclose
 
Laia Garrigós
Speakers' Bureau - Daiichi Sankyo; Novartis
 
Melissa Fernández
Employment - MedSIR
 
Olga Boix
Employment - MedSIR
Patents, Royalties, Other Intellectual Property - MedSIR
 
Daniel Alcalá-López
Employment - MedSIR
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MAJ3 Capital
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung; Steamline Therapeutics
Consulting or Advisory Role - Abbvie; AstraZeneca; Athenex; Bioasis; Biocon; Bioinvent; BioNTech SE; Boehringer Ingelheim; Bridgebio; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; Ellipses Pharma; ERYTECH Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; HiberCell; Jazz Pharmaceuticals; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); Astrazeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Merck Sharp&Dhome; Novartis; Pfizer; Roche; Steamline Therapeutics
 
Antonio Llombart
No Relationships to Disclose